Efmody^® is a modified-release hydrocortisone therapy that addresses a critical need in the management of congenital adrenal hyperplasia (CAH), offering a new treatment opportunity for patients with this rare genetic condition.

EffRx recently received from Swissmedic the Marketing Authorization for Efmody^® and is aiming for a market launch in 2024.

The approval and planned market launch of Efmody^® in Switzerland is a testament to EffRx’s commitment to expanding access to essential therapies for rare conditions, and emphasizes its role in transforming patient care in the field of congenital adrenal hyperplasia.